Quality of life: a new prognostic indicator in advanced hepatocellular carcinoma

  • Published 2006 in Nature Clinical Practice Oncology

Abstract

11% higher in the aprepitant group than in the control group (P = 0.003). Aprepitant therapy was most notably superior to the control regimen in preventing vomiting during the delayed phase of chemotherapy (24–120 h postcisplatin; P ≤0.001). Patients receiving the aprepitant regimen also had a significantly longer time to first vomiting episode than those… (More)
DOI: 10.1038/ncponc0574

Topics

Cite this paper

@article{2006QualityOL, title={Quality of life: a new prognostic indicator in advanced hepatocellular carcinoma}, author={}, journal={Nature Clinical Practice Oncology}, year={2006}, volume={3}, pages={468-468} }